Legal Representation
Attorney
Bret E. Field
USPTO Deadlines
Application History
36 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 12, 2024 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| May 27, 2024 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Oct 25, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 24, 2023 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Oct 16, 2023 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Oct 16, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 19, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 17, 2023 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Apr 17, 2023 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Apr 17, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 19, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 17, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Oct 17, 2022 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Oct 17, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 19, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 15, 2022 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Apr 15, 2022 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Apr 15, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 28, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 27, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Oct 25, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 18, 2021 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Oct 18, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 20, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Feb 23, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 23, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 3, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 15, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 14, 2021 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jan 14, 2021 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jan 13, 2021 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 13, 2021 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 13, 2021 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jan 8, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 8, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 7, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; pharmaceutical preparations, compositions, creams and lotions for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations, namely, transdermal gel formulations, transdermal cream formulations, oral mucous formulations, transdermal patches, dressings and medical adhesive tapes for use in the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions
Classification
International Classes
005